College of American Pathologists
CAP Committees & Leadership CAP Calendar of Events Estore CAP Media Center CAP Foundation
 
About CAP    Career Center    Contact Us      
Search: Search
  [Advanced Search]  
 
CAP Home CAP Advocacy CAP Reference Resources and Publications CAP Education Programs CAP Accreditation and Laboratory Improvement CAP Members
CAP Home > CAP Members > Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

title

Updated July 14, 2014

Recommendations

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have developed an evidence-based guideline which establishes recommendations for EGFR and ALK testing, helping to guide targeted therapies. The guideline was released on April 3, 2013, in Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology, and The Journal of Molecular Diagnostics.

The guideline provides answers to these important clinical questions:

  • When should testing be performed?
  • How should EGFR testing be performed?
  • How should ALK testing be performed?
  • Should other genes be routinely tested in lung cancer?
  • How should molecular testing of lung cancer be implemented?

The implementation of the CAP/IASLC/AMP guideline will ensure a uniform approach to the molecular testing of lung cancer and will improve the effectiveness of lung cancer treatment for patients.

Guideline and Supplemental Digital Content Guideline and Supplemental Digital Content

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Detailed information regarding the project’s comprehensive literature review, evidence grading and conflict of interest policy, etc., may be accessed in the Supplemental Digital Content available online within the manuscript.

Resources Resources

Summary of Recommendations

Access Presentation Slides from April 24, 2013 Webcast with the Lead Authors of the Guideline

See Frequently Asked Questions (PDF, 73 KB) for further information.

Read the CAP TODAY Article on “New guidance on lung cancer testing

Information for Patients Information for Patients

Read the Patient Guide (PDF, 368 KB) for further information.

LAST Consensus Recommendations Feedback Feedback

Comment on the Recommendations

Related Links Related Links

 
 © 2014 College of American Pathologists. All rights reserved. | Terms and Conditions | CAP ConnectFollow Us on FacebookFollow Us on LinkedInFollow Us on TwitterFollow Us on YouTubeFollow Us on FlickrSubscribe to a CAP RSS Feed